Last reviewed · How we verify
Adjuvant immunotherapy
Adjuvant immunotherapy enhances the body's immune system to recognize and eliminate residual cancer cells after primary treatment.
Adjuvant immunotherapy enhances the body's immune system to recognize and eliminate residual cancer cells after primary treatment. Used for Adjuvant treatment in cancer patients (specific cancer type and stage under investigation in phase 3 trial).
At a glance
| Generic name | Adjuvant immunotherapy |
|---|---|
| Also known as | postoperative adjuvant immunotherapy |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adjuvant immunotherapy is administered following surgery, chemotherapy, or radiation to boost anti-tumor immune responses and reduce recurrence risk. It typically works by activating T cells, enhancing checkpoint inhibition, or promoting dendritic cell-based immunity to target micrometastatic disease that may persist after initial treatment.
Approved indications
- Adjuvant treatment in cancer patients (specific cancer type and stage under investigation in phase 3 trial)
Common side effects
- Immune-related adverse events (fatigue, fever, rash)
- Injection site reactions
- Lymphopenia
Key clinical trials
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer (PHASE1)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (PHASE3)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |